Strong efficacy but serious side-effects with Spark’s haemophilia drug drop shares by 30%
pharmafile | August 8, 2018 | News story | Research and Development | Spark Therapeutics, haemophilia, pharma
Spark Therapeutics has been left reeling after it revealed new data on its haemophilia A treatment, which, while promising in efficacy, left investors disappointed and share price plummeting.
Haemophilia is a rare blood disorder affecting around 20,000 in the US. In those with the condition, blood fails to clot properly due to a deficiency of a protein known as Factor VIII. Spark’s therapy, known as SPK-8011, reduced bleeds and the need for infusions by 97% when tested in 12 patients in three different dosage levels. In the highest dose, five of seven patients saw Factor VIII levels rise to 30% of normal on average.
However, two of these seven patients responded negatively to the therapy, with their Factor VIII levels dropping to below 5%, and one of the patients experienced a serious adverse event, rendering them hospitalised. The news left shareholders dissatisfied in the drug’s performance, and shares in the company fell by almost a third.
“The clinical and safety profile of SPK-8011 has been highly encouraging, with no FVIII inhibitors observed. Transaminase elevations above the upper limit of normal have been seen in only three of 12 participants, with no evidence of persistent transaminase elevations,” said Dr Katherine A High, President and Head of Research and Development at Spark. £We believe, based on the tempo and magnitude of the immune responses observed, that a prophylactic course of steroids will suppress these responses and should lead to long-term expression of FVIII above 12% in all participants at a dose of 2×1012 vg/kg of SPK-8011. We plan to implement this prophylactic approach to steroid administration moving forward.
“These early data further support the dramatic impact on patient outcomes that can result from factor activity levels above 12% and bring us closer to our goal of one day eliminating spontaneous bleeding altogether, while potentially freeing patients with haemophilia A from the need for regular infusions,” she continued.
Despite the issues identified in the trial, Spark confirmed plans to take the highest dose of the therapy through to Phase 3, with a run-in study scheduled for the fourth quarter of this year.
Matt Fellows
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
FDA approves BioMarin’s Roctavian for adults with severe haemophilia A
Global biotechnology company BioMarin Pharmaceuticals has announced that the US Food and Drug Administration (FDA) …
